The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy

Similar documents
DISTAL PULMONARY THROMBOENDARTERECTOMY: IS IT WORTH IT?

Surgical Management in Chronic Thromboembolic Pulmonary Hypertension. Michael Bates, MD, FACS Ochsner Health System, New Orleans, LA

Pulmonary Hypertension Surgical Options. Primary pulmonary hypertension. Transplantation. Thromboembolic disease Endarterectomy

CTEPH. surgical treatment. Ph. Dartevelle, E. Fadel, S. Mussot, D. Fabre, O. Mercier and G. Simonneau PARIS-SUD UNIVERSITY

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program

Selection criteria for PEA (UCSD)

Standard AVR. Full Sternotomy CPB

Real life management of CTEPH: patient case

Ann Vasc Dis Vol. 6, No. 3; 2013; pp Online August 12, Annals of Vascular Diseases doi: /avd.oa Original Article

Severe pulmonary embolism: surgical aspects. Oliver Reuthebuch Clinic for Cardiac Surgery University Hospital Basel Switzerland

Less Invasive Reoperations for Aortic and Mitral Valve Disease. Peter Bent Brigham Hospital 1913

Right Ventricular Failure: Prediction, Prevention and Treatment

Declaration of conflict of interest NONE

The management of chronic thromboembolic pulmonary

Pulmonary thromboendarterectomy (PTE) is indicated for

Αγγειοπλαστική των πνευμονικών αρτηριών στην χρόνια θρομβοεμβολική πνευμονική υπέρταση. Παρόν και μέλλον

CARDIOCHIRURGIA MINI-INVASIVA: INVASIVA: efficacia per il paziente efficienza per la sanita. Dott. Davide Ricci

Thinking outside of the box Perfusion management and myocardial protection strategy for a patient with sickle cell disease

Outline. Congenital Heart Disease. Special Considerations for Special Populations: Congenital Heart Disease

ECMO vs. CPB for Intraoperative Support: How do you Choose?

Minimally invasive video-assisted mitral valve surgery: the CardioMISS experience in more than 200 cases

Minimally Invasive Mitral Valve Repair: Indications and Approach

Επεμβατικές στρατηγικές στην πνευμονική υπέρταση

Minimally invasive aortic valve surgery: new solutions to old problems.

Steph ani eph ani Mi M ck i MD Cleveland Clinic

Mitral Repair/AF Ablation Sternotomy Approach

Medical Management of CTEPH: What is its role?

Less Invasive Aortic Valve Surgery

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Learning Objectives. Outline. CTEPH: Practice Guidelines. History. 36 y/o Man with Chest Pain and Dyspnea

WHAT IS. Helping your patients understand their type of PH. Educational program by. Material endorsed by

ACTIVITY DESCRIPTION Target Audience Learning Objectives

TERMS TOTAL ENDOSCOPIC ROBOTIC MITRAL SURGERY 3/17/2016 ROBOTIC MITRAL VALVE HISTORY PREPARED BY: DIANA FROEHLICH, CCP & AKILAH RICHARDS, CCP

PhD in Bioengineering and Medical-Surgical Sciences

Pulmonary Endarterectomy: Assessment of Operability, Surgical Description, and Post-op Care

OPCAB IS NOT BETTER THAN CONVENTIONAL CABG

WHAT IS CTEPH. Helping you understand your type of PH. Provided by Bayer to help education of the PH community

Experience with 500 Stentless Aortic Valve Replacements

Minimally Invasive Aortic Surgery With Emphasis On Technical Aspects, Extracorporeal Circulation Management And Cardioplegic Techniques

AVR with Sutureless Valves State of the Art

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer

Cath Lab Essentials: Basic Hemodynamics for the Cath Lab and ICU

Glenn Shunts Revisited

2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD

Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS

Chronic Thromboembolic Pulmonary Hypertention CTEPH

Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension

Cardiac Valve/Structural Therapies

Minimally invasive aortic valve surgery: Cleveland Clinic experience

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.

Simplifying Techniques and Goals to allow for Less Invasive Surgery

Pulmonary Hypertension in 2012

The Role of ECMO in Thoracic Surgery. Matthew Hartwig, MD

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

Remodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery

EACTS Adult Cardiac Database

Surgical Thrombectomy for PE: Is it Making a Comeback

Mabel Labrada, MD Miami VA Medical Center

European Robotic Forum March 2018 Tampere - Finland

Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension

Dr Nikolaos Baikoussis

WHAT IS CTEPH. Helping you understand your type of PH. Provided by Bayer to help education of the PH community

Alfa Ferry FRCS Cardiac Surgeon OPERATIVE MANAGEMENT IN CORONARY ARTERY DISEASE

CTED and the Value of Exercise Testing

Repair of Complete Atrioventricular Septal Defects Single Patch Technique

The Double Switch Using Bidirectional Glenn and Hemi-Mustard. Frank Hanley

Is bypass surgery needed for elderly patients with LMT disease? From the surgical point of view

Antegrade Thoracic Stent Grafting during Repair of Acute Debakey I Dissection: Promotes Distal Aortic Remodeling and Reduces Late Open Re-operation

Minimally invasive direct coronary artery bypass for left anterior descending artery revascularization analysis of 300 cases

Innovative ECMO Configurations in Adults

Use of EKOS Catheter in the management of Venous Mr. Manoj Niverthi, Mr. Sarang Pujari, and Ms. Nupur Dandavate, The GTF Group

Management of Heart Failure in Adult with Congenital Heart Disease

Ischemic Ventricular Septal Rupture

APOLLO TMVR Trial Update: Case Presentation

Blood Management of the Cardiac Patient in the Postoperative Period

Percutaneous Transapical Access for Thoracic Endovascular Repair

An anterior aortoventriculoplasty, known as the Konno-

Pulmonary Hypertension: Another Use for Viagra

Aggressive Resection/Reconstruction of the Aortic Arch in Type A Dissection

Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi

From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

MICS CABG. Putting the future of MICS in your hands today

2/7/2018. Minimally-invasive Mitral Valve surgery at NYU

ΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH)

Screening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden

Central extracorporeal membrane oxygenation for treatment of reperfusion oedema following pulmonary thromboendarterectomy: a case report

Management of Acute Aortic Syndromes. M. Grabenwoger, MD Dept. of Cardiovascular Surgery Hospital Hietzing, Vienna, Austria

Quantifying the learning curve for pulmonary thromboendarterectomy

Technical option of surgical approach for trouble-shooting

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

SELECTIVE ANTEGRADE TECHNIQUE OF CHOICE

Introduction. Study Design. Background. Operative Procedure-I


Chronic thromboembolic pulmonary hypertension (CTEPH) and the essential role of imaging specialists PP-ADE-ALL

Pulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical

Society of Thoracic Surgeons Implementation of a Surgical Curriculum in Cardiothoracic Surgery January 27, 2014

Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS

Evaluating the Post Pulmonary Embolism Patient: What You Need to Know

Incidence of Postoperative Atrial Fibrillation after minimally invasive mitral valve surgery

Transcription:

The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy Michael M Madani, MD, FACS Professor & Chief, Cardiovascular & Thoracic Surgery Director, UCSD - Surgery University of California San Diego

Disclosure No conflict with this presentation Consultant Bayer Actelion Wexler Surgical

Midterm Results Operated (60%) Non-operated (40%) Age (years) 60 67 PAP (mmhg) 48 45 PVR (dyn sec cm 5 ) 728 676 NYHA I-II/III/IV (%) 19/69/12 18/69/13 PAP, pulmonary artery pressure. ICA European registry data. Delcroix M et al. Circulation 2016;133:859.

Treatment of CTEPH in 2017: PTE, BPA, Medical Therapy Adapted from: Madani, Ogo, Simonneau, The changing landscape of chronic thromboembolic pulmonary hypertension management, in Press ERR 2017. Vessel diameter Lesion types φ 3cm Fibrotic clots φ 2mm φ 0.1-0.5mm Microvasculopathy (Intimal thickening and proliferation)

Determination of Operability Extremely important as surgical therapy can be potentially curative Challenging Multifactorial Need more clear definition of Operability or Resectability vs Surgical Candidacy Requires an expert CTEPH team

Factors in Patient Selection Severity of patient s symptoms Severity of PH and RV dysfunction Extent and level of obstruction (high-quality imaging) Severity of the PH versus the degree of obstruction Patient s Comorbidities Technical concerns ( hostile chest ) A clear assessment of risk/benefit ratio based on the patient s individual expectation and acceptance of the risks Sulpizio Cardiovascular 7 Center

Potential Red Flags: Limited distal disease and severe PH Parenchymal lung disease LV diastolic dysfunction Advanced Age Acceptable outcomes in octogenarians Venous access catheters VA shunts Pacemaker leads Splenectomy Sickle Cell Anemia

Factors considered in Evaluation and CTEPH operability assessment Reliable and Precise Imaging Surgeon s experience # s, outcomes, distal disease Clot burden Operability Hemodynamics Center s experience Patient factors: Age, comorbidities, Technical

Illustration courtesy of Hotten, M. Thesis, Master Scientific Illustration, 2016. 1-Jamieson et al. Cur Prog Surg 2000, 37:165-252 2-Madani et al. Op Tech in Tho & Card Surg 2006, 11:264-274

Who benefited from surgery? PVR 1169 to 294 PVR 1290 to 204 PVR 858 to 365 PVR 527 to 188

UC San Diego Experience Total Number ~ 3800 Mortality 1-2%

1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 UCSD Experience 250 PTE Volume per Year 200 150 100 50 0

Recent Advances: Surgery More distal disease resection Refinements in imaging, instruments and surgical techniques allow distal resection Higher risk patients Severe PH Severe RHF Morbid Obesity Elderly, PTE in octogenarians Better ability to address post-op compilations Pulmonary Reperfusion Injury Residual PH Hemoptysis

Despite clear advantage of surgery, new advances, and many new centers, only about 300-350 PTEs are performed in the US Physician Factors: Delay in Diagnosis Treatment options Delay in Referral Uncertainty about outcomes Self-screening of patients Patient Factors: Personal reasons Risks Proximity of the center AND Fear of surgery

Pushing the boundaries Relying on: Advancements in MIS valve and CABG operations and gained experience Understanding the potential pitfalls and contraindications Availability of newer imaging technology and disease correlation Improved Surgical instruments All Leading to laboratory work and development of MIS PTE Techniques Professor Heinz Günther Jakob in Essen

Definition of MIS cardiac surgery Variety of definitions: Based on Access Partial Sternotomy Mini Anterior or Lateral Thoracotomies / Avoidance of sternotomy Port access and endoscopic Robotic Assisted Robotic Avoiding CPB? Off-pump CABG

MIS Cardiac Surgery

Sternotomy In Other Cardiac Procedures Drawbacks Patient s Perception Long recovery period 2-3 months for full recovery Longer Hospital Stay Higher risk of infection Blood utilization Cosmetics Competing with growing catheter based interventions as well as medical therapy Advantages: Proven technique and safety Faster operating times: OR, CPB, X-Clamp No need for peripheral cannulation Easier aortic cross-clamping Perhaps more secure cardiac protection and de-airing

Results of Minimally Invasive Valve Surgeries Similar short and long-term outcomes Shorter Ventilation Times Shorter ICU stays Shorter hospital Stay Decrease in post-op bleeding Lower infection rate Lower Blood Transfusion Rates Earlier Return to Work Tomislav Mihaljevic, et al Annals of Surgery Volume 240, Number 3, September 2004 Joseph Lamelas, et al, Semin in Th & Cardiovasc Surg, Volume 27, Issue 1, Spring 2015, Ismail Bouhout, et al, Canadian Journal of Cardiology, Volume 33, Issue 9, September 2017

Early in our experience Recurrent quotes from my mentor running through my head The system is working perfectly fine, until some idiot comes along and tries to change it Why change decades of success? It takes a genius to make things simple, any idiot can make it more complicated Why take an operation and make it even more challenging?

Minimally Invasive and yet maximally painful for the surgeon

But Why? Better appeal, Faster Recovery, and Better Outcomes

Increasing Threat of Percutaneous Options

HOW?

Keeping the main principles: CPB and cooling Circulatory arrest for a perfect visualization Clear identification of the correct plane Full bilateral Endarterectomy Avoid Sternotomy

Issues to Address Perfusion and CPB Aortic Cross clamp and myocardial protection Exposure of the vessels Visualization? Inability to move the heart

Perfusion Consideration Aortic / Arterial Can be Central or Peripheral Distal antegrade perfusion of the leg Surface oximetry reading of both legs Venous Multi-stage peripheral venous cannulation with tip of the cannula in the SVC In larger patients, or patients with IVC filter, Additional cannulation can be performed directly in the right atrium or through IJ line.

Peripheral Cannulation

Cannulation and Myocardial Protection If aortic cross clamp is utilized: Direct aortic root administration of cardioplegia Del Nido at 45 minute intervals But in PTEs: Since circ arrest times are 20 minute intervals, surgery can be performed without X-clamp Smaller incision on the right side

Central Aortic Cannulation Highly Valuable Space Avoiding X-Clamp and Venous cannulation Provides more room

Pre-Discharge Photo POD 9

Pre & Post V/Q scans

Unilateral Disease

Pre & Post V/Q Scans

Results MIS Patient 1 MIS Patient 2 MIS Patient 3 MIS Patient 4 MIS Patient 5 MIS PTE (mean) (n 5) Sternotomy PTE (mean) (n 918) History 39 y/o F, exercise induced dyspnea with complete occlusion RML/RLL 27 y/o F, history of LE DVT, complete occlusion of LPA 15 y/o M, Hx PE, DVT, antiphospholipi d antibody syndrome, polysubstance abuse 35 y/o M Hx DVT, methamphetam ine use, Factor V Leiden 43 y/o M hx PE, MTHFR gene mutation Age (mean) 31.8 years Age (mean) 51.9 years Circulatory arrest times UCSD Classification Disease Level Right: 9min Left: 4min Right- level 2 Left- level 0 Right:13min Left-:15min Right- level 3 Left- level 1C Right: 20+8 Left: 20+14 Right: level 1 Left: level 1 Right: 18min Left : 19min Right: Level 1 Left: Level 2 Right: 0 Left: 17min Right: Level 0 Left: Level 1C (mean) 31.4 min (mean) 46.56 min PVR dynes.s.cm-5 Pre- 173 Post - 116 Postop LOS Pre- 386 Post- 196 Pre-1000 Post-271 Pre-311 Post-108 Pre- 462 Post-114 8 days 12 days 10 days 9days 10 days (mean) Pre-466.4 Post-161 (mean) 9.8 days (mean) Pre- 670.47 Post- 245.35 (mean) 13.4

Current Limitations: Morbid Obesity / Increased BMI Significant chest wall collaterals Severe PH and RV failure IVC filter Disease limited to segmental or subsegmental vessels only Prior thoracotomies Unsuitable chest and great vessels anatomy

Factors considered in CTEPH operability assessment for MIS Patient s Height and Weight Clot burden Reliable and Precise Imaging Prior Thoracotomies Operability Surgeon s experience # s, outcomes, distal disease Need of Concomitant procedures Hemodynamics Anatomy of the chest and mediastinal Structures Center s experience Patient factors: Peripheral vascular disease, Organ Patient factors: Dysfunction Age, comorbidities, Technical Severe PH, RV Failure

Conclusion PTE surgery remains the best treatment option and should always be the first line of treatment for CTEPH MIS PTE is in its infancy, but it offers comparable visualization and appears safe Requires judicious patient selection. Good early outcomes The key ingredient to innovation and success is the support of an excellent and dedicated team

Thank you!